Added to YB: 2026-07-17
Pitch date: 2026-07-16
NVO [neutral]
Novo Nordisk A/S
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
N/A
Price Target
N/A
Dividend
3.66%
EV/EBITDA
8.77
P/E
11.66
EV/Sales
4.70
Sector
Pharmaceuticals
Category
growth
Show full summary:
Novo Nordisk A/S ($NVO)
NVO (update): EU Commission approves Wegovy oral GLP-1 pill (5th approval after US, UK, UAE, Bahrain) + 7.2mg high-dose pen. First tablet-form GLP-1 for weight mgmt in EU. Oral launch strong: Novo capturing 89% of new pill Rx volume vs Lilly's Foundayo 11% since April.
Read full article (1 min)